Concepedia

Barbara Zheng

BZ

6

Publications

277

Citations

6

H-Index

2014

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Biocon (India)

Bristol-Myers Squibb (India)

Barbara Zheng is an author at Bristol-Myers Squibb (United States) specializing in drug resistance, medicine, and drug discovery.

ORCID

Top concepts

Publications per year

2014–2022

6

Publications

6

The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Paul M. Scola, Li‐Qiang Sun, Alan Xiangdong Wang et al. · Journal of Medicinal Chemistry · 2014 · 109 citations

Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good et al. · Journal of Medicinal Chemistry · 2014 · 66 citations · Full text

Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor

Barbara Zheng, Stanley V. D’Andrea, Li‐Qiang Sun et al. · ACS Medicinal Chemistry Letters · 2018 · 38 citations · Full text

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing

Li‐Qiang Sun, Eric Mull, Barbara Zheng et al. · Journal of Medicinal Chemistry · 2016 · 30 citations · Full text

, , +20

Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Li‐Qiang Sun, Eric Mull, Stanley V. D’Andrea et al. · Journal of Medicinal Chemistry · 2020 · 22 citations · Full text

Rows per page

1–5 of 6